Loading...
•
Sep 30, 2023
Tenaya Therapeutics Q3 2023 Earnings Report
Reported financial results and provided a corporate update.
Key Takeaways
Tenaya Therapeutics reported its Q3 2023 financial results, highlighting the commencement of patient dosing in the MyPeak-1 Phase 1b trial of TN-201 and the FDA clearance for TN-401 to begin clinical testing. The company's cash, cash equivalents, and investments are expected to fund operations into the first half of 2025.
Dosed first patient in MyPeak-1 Phase 1b clinical trial of TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy.
Shared interim results from seroprevalence study indicating low levels of preexisting neutralizing antibodies to AAV9 in patients with MYBPC3-associated HCM.
FDA cleared clinical testing of TN-401 and granted Fast Track Designation.
Shared positive Phase 1 data for TN-301 at the 2023 Heart Failure Society of America (HFSA) Annual Scientific Meeting.
Forward Guidance
Tenaya expects current cash, cash equivalents and investments in marketable securities will be sufficient to fund the company into the first half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...